EGFR R521K Polymorphism Is Not a Major Determinant of Clinical Cetuximab Resistance in Head and Neck Cancer.

Mihály CserepesGyörgyi A NelhűbelMónika Meilinger-DobraAdrienn HerczegDóra TürkZita HegedűsLaura SvajdaErzsébet RásóAndrea LadányiKristóf György CsikóIstván KenesseyÁrpád SzöőrGyorgy VerebÉva RemenárJózsef Tóvári

Published in: Cancers (2022)

Our results suggest that EGFR R521K, unlike reported previously, is unable to cause cetuximab resistance in HNSCC patients; therefore, its screening before therapy selection is not justifiable.

Keyphrases

small cell lung cancer
end stage renal disease
epidermal growth factor receptor
tyrosine kinase
ejection fraction
chronic kidney disease
newly diagnosed
peritoneal dialysis
locally advanced
prognostic factors
stem cells
radiation therapy
cell therapy